PUBLICATION

Aquatic toxicology of fluoxetine: Understanding the knowns and the unknowns

Authors
Stewart, A.M., Grossman, L., Nguyen, M., Maximino, C., Rosemberg, D.B., Echevarria, D.J., Kalueff, A.V.
ID
ZDB-PUB-140924-8
Date
2014
Source
Aquatic toxicology (Amsterdam, Netherlands)   156: 269-73 (Journal)
Registered Authors
Maximino, Caio
Keywords
Antidepressants, Aquatic model, Ecotoxicology, Fluoxetine, Neuroscience, Zebrafish
MeSH Terms
  • Animals
  • Aquatic Organisms/drug effects*
  • Behavior, Animal/drug effects*
  • Ecotoxicology/standards*
  • Fluoxetine/toxicity*
  • Models, Animal
  • Serotonin/metabolism
  • Water Pollutants, Chemical/toxicity
  • Zebrafish
PubMed
25245382 Full text @ Aquat. Toxicol.
Abstract
Fluoxetine is one of the most prescribed psychotropic medications, and is an agent of increasing interest for environmental toxicology. Fish and other aquatic organisms are excellent models to study neuroactive small molecules like fluoxetine. However, prone to variance due to experimental factors, data obtained in these models need to be interpreted with caution, using proper experimental protocols, study designs, validated endpoints as well as well-established models and tests. Choosing the treatment protocol and dose range for fluoxetine and other serotonergic drugs is critical for obtaining valid test results and correct data interpretation. Here we discuss the value of aquatic models to study fluoxetine effects, based on prior high-quality research, and outline the directions of future translational studies in the field. We review fluoxetine-evoked phenotypes in acute vs. chronic protocols, discussing them in the contact of complex role of serotonin in behavioral regulation. We conclude that zebrafish and other aquatic models represent a useful in-vivo tool for fluoxetine pharmacology and (eco)toxicology research.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping